NCT02064387View on ClinicalTrials.gov

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

July 29, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 1, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

GSK2857916

A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.

Trial Locations (9)

10065

GSK Investigational Site, New York

19104

GSK Investigational Site, Philadelphia

98109

GSK Investigational Site, Seattle

02215

GSK Investigational Site, Boston

27599-7600

GSK Investigational Site, Chapel Hill

75390-8565

GSK Investigational Site, Dallas

V5Z 1M9

GSK Investigational Site, Vancouver

M5G 2M9

GSK Investigational Site, Toronto

NW1 2BU

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02064387 - Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 | Biotech Hunter | Biotech Hunter